Design and Synthesis of Peptide-based Therapeutics to Combat Antimicrobial Resistance

Henrike Navarro^*
*Correspondence: Henrike Navarro, Department of Laboratory Medicine, General Hospital of Amfissa, Amfissa, Greece, Email:

Introduction

Antimicrobial Resistance (AMR) has emerged as one of the most significant global health threats of the 21st century. The overuse and misuse of antibiotics in medicine, agriculture and animal husbandry have accelerated the development of resistant strains of bacteria, fungi and other pathogens, rendering many traditional antibiotics ineffective. As a result, common infections, minor surgeries and conditions that were once easily treatable with antibiotics have become increasingly difficult to manage, leading to longer hospital stays, higher medical costs and increased mortality rates. Furthermore, peptides can be engineered to target specific bacterial processes or structures, allowing for the development of more selective and potentially less toxic therapies. Peptide-based therapeutics, often referred to as antimicrobial peptides (AMPs), are naturally occurring molecules found in various organisms, including humans, plants and animals. These peptides function as part of the innate immune system, serving as a first line of defence against infections. A versatility and ability to target a broad range of pathogens, including multidrug-resistant bacteria, make them attractive candidates for the development of next-generation therapeutics. The synthesis and design of peptide-based therapeutics to combat antimicrobial resistance represents an exciting frontier in the search for new antibiotics. This approach offers the potential not only to address existing resistance but also to stay ahead of evolving pathogens, offering hope for a future in which antimicrobial resistance is no longer a barrier to effective treatment [1].

Description

Antimicrobial Resistance (AMR) has emerged as one of the most pressing global health threats in recent decades. The widespread and often inappropriate use of antibiotics in both clinical and agricultural settings has contributed to the rapid development of resistance in bacteria, fungi and other pathogens, rendering many of our most commonly used antibiotics ineffective. This phenomenon threatens to undo decades of medical progress and leaves us vulnerable to infections that were once easily treatable. Conditions such as pneumonia, tuberculosis, urinary tract infections and even minor surgical procedures could become fatal once again if antimicrobial resistance continues to increase unchecked. Peptides are short chains of amino acids that play essential roles in various biological processes, including immune response, cell signaling and the regulation of microbial populations. Antimicrobial Peptides (AMPs), which are naturally occurring molecules found in a variety of organisms, including humans, animals, plants and microorganisms, represent a key component of the innate immune system. These peptides act as a first line of defense against infections by directly targeting and disrupting the membranes of pathogens. In addition to their direct antimicrobial effects, AMPs can modulate immune responses, enhance wound healing and work synergistically with other antimicrobial agents. This broad range of biological activities makes AMPs highly attractive candidates for the development of new therapeutics aimed at addressing the growing problem of AMR [2].

AMPs are typically cationic (positively charged) and amphipathic, meaning they possess both hydrophobic and hydrophilic regions. This unique structural feature allows AMPs to interact with and penetrate the negatively charged membranes of bacteria, fungi and viruses, causing membrane disruption and subsequent cell death. Their mechanism of action is distinct from that of conventional antibiotics, which typically target specific bacterial processes such as protein synthesis, cell wall biosynthesis, or DNA replication. Because of their ability to act on multiple pathogens through different mechanisms, AMPs have the potential to target a broad range of microorganisms, including those that have developed resistance to traditional antibiotics. Additionally, AMPs have been shown to be effective against multidrug-resistant (MDR) strains of bacteria, making them particularly valuable in the fight against AMR. The potential of AMPs as therapeutics has attracted considerable attention in recent years. Natural AMPs, such as defensins, cathelicidins and lactoferrin, have been identified as important components of the innate immune system. These peptides are produced by a wide variety of organisms, including humans and exhibit potent antimicrobial properties. The short half-life of many AMPs in the bloodstream and their susceptibility to proteolytic cleavage limit their therapeutic potential. As a result, extensive research has been devoted to improving the stability, efficacy and safety of peptide-based therapeutics [3].

One of the primary challenges in developing AMPs as clinical agents is their susceptibility to degradation by enzymes in the body. The presence of proteases, particularly in the gastrointestinal tract and bloodstream, can rapidly break down AMPs, reducing their effectiveness. To overcome this limitation, researchers have developed strategies to modify peptide structures to increase their stability. For instance, incorporating non-natural amino acids, such as D-amino acids or cyclic peptides, can enhance the resistance of AMPs to enzymatic degradation. These modifications can also improve the binding affinity of the peptides for bacterial membranes, further increasing their antimicrobial potency. In addition, modifications to the peptide sequence can help reduce toxicity, which is another concern with the use of natural AMPs. Many AMPs are cytotoxic at high concentrations and their use as therapeutics must be carefully balanced to avoid harming healthy cells. Another promising strategy for improving the therapeutic potential of AMPs is the development of peptide-drug conjugates or nanoparticle-based delivery systems. These approaches aim to enhance the delivery and bioavailability of peptides while minimizing off-target effects. This combination approach could enhance the overall therapeutic effect and reduce the likelihood of resistance developing [4].

The development of peptide-based therapeutics also benefits from the advances in computational methods, such as molecular modeling and high-throughput screening techniques. These tools allow researchers to predict the structure-activity relationships of AMPs and identify new peptides with enhanced antimicrobial properties. Computational approaches can also help design peptides that target specific bacterial processes or structures, such as bacterial cell wall components or virulence factors. By focusing on these targets, researchers can design highly selective AMPs that minimize off-target effects and reduce the risk of toxicity. Despite the promising potential of peptide-based therapeutics, several challenges remain in translating these agents into clinical practice. One of the major hurdles is the cost of synthesizing peptides on a large scale. While Solid-Phase Peptide Synthesis (SPPS) has made it possible to synthesize peptides with high purity and specificity, the process can be expensive and time-consuming, particularly for longer peptides or those with complex modifications. Researchers are working on developing more efficient and cost-effective methods for peptide synthesis, including the use of recombinant DNA technology and bacterial expression systems. The stability of peptides in various formulations, as well as their ability to penetrate tissue and reach the site of infection, must be optimized for successful clinical use. Therefore, extensive testing and optimization are required to ensure that peptide-based therapeutics is safe, effective and well-tolerated in humans [5].

Conclusion

In conclusion, the design and synthesis of peptide-based therapeutics represent a promising strategy to combat antimicrobial resistance. Although challenges related to stability, toxicity and synthesis remain, significant progress has been made in enhancing the potency, selectivity and safety of peptide-based agents. Advances in peptide engineering, drug delivery systems and computational design are opening up new possibilities for developing effective treatments against multidrug-resistant pathogens. As the global threat of antimicrobial resistance continues to escalate, peptide-based therapeutics offer hope for the development of innovative solutions to address this urgent public health crisis. Through continued research and development, peptides may one day play a central role in the fight against infections that threaten to undermine modern medicine.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Aslam, Bilal, Wei Wang, Muhammad Imran Arshad and Mohsin Khurshid, et al. "Antibiotic resistance: A rundown of a global crisis." Infect Drug Resist (2018): 1645-1658.

Google Scholar        Cross Ref                Indexed at

2. Maron, Dina Fine, Tyler JS Smith and Keeve E. Nachman. "Restrictions on antimicrobial use in food animal production: An international regulatory and economic survey." Glob Health 9 (2013): 1-11.

Google Scholar        Cross Ref                Indexed at

3. Mulkern, Adam J., Linda B. Oyama, Alan R. Cookson and Christopher J. Creevey, et al. "Microbiome-derived antimicrobial peptides offer therapeutic solutions for the treatment of Pseudomonas aeruginosa infections." Npj Biofilms Microbiomes 8 (2022): 70.

Google Scholar        Cross Ref                Indexed at

4. Van Eijk, Martin, Stephanie Boerefijn, Lida Cen and Marisela Rosa, et al. "Cathelicidin-inspired antimicrobial peptides as novel antifungal compounds." Med Mycol 58 (2020): 1073-1084.

Google Scholar        Cross Ref                Indexed at

5. Hao, Xue, Hailong Yang, Ling Wei and Shilong Yang, et al. "Amphibian cathelicidin fills the evolutionary gap of cathelicidin in vertebrate." Amino Acids43 (2012): 677-685.

Google Scholar        Cross Ref                Indexed at